ENDO 2026: Palsonify Long-Term OLE and Atumelnant Ph2 CAH Full Results

Research evidence excerpt

ENDO 2026: Palsonify Long-Term OLE and Atumelnant Ph2 CAH Full Results

t of Normal (ULN) at baseline to 0.82x ULN at 48 Q4 (1.29) - (1.16) - -

weeks (n=50) and 0.81x ULN at 96 weeks (n=47). For 103 of 106 patients who e = Morgan Stanley Research estimates, a = Actual Company reported data

entered from PATHFNDR-2 (biochemically uncontrolled acromegaly patients) with 11

additional patients who enrolled directly, IGF-1 levels remained stable, from 1.64x

Upper Limit of Normal (ULN) at baseline to 1.06x ULN at 48 weeks (n=98) and

0.96x ULN at 72 weeks (n=78). Symptoms associated with acromegaly, as measured

by the Acromegaly Symptom Diary (ASD), remained stable from baseline at

assessed timepoints. Treatment also resulted in stable or reduced pituitary tumor

volumes for up to 48 weeks. No new safety signals were found. Four patients (2.4%)

discontinued from an OLE due to adverse events as of this analysis. Additional

ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and

cabergoline combination improves biochemical control of acromegaly

(presentation). Combination therapy was well tolerated.

Crinetics presented full Ph2 atumelnant data at Week 12, which support best-in-

class A4 reductions. Following positive topline data for the first 3 dose cohorts of

the atumelnant Phase 2 TouCAHn study and Cohort 4 (see notes HERE and HERE),

Crinetics presented full results at ENDO 2026 (presentation). Recall, patients in

Cohort 4 received atumelnant (80 mg) once daily in the morning and underwent Morgan Stanley does and seeks to do business with

glucocorticoid (GC) dose reduction toward physiologic levels (<11 mg/m2/day companies covered in Morgan Stanley Research. As a result,

investors should be aware that the firm may have a conflict of